Progress in the treatment of myasthenia gravis

Therapeutic Advances in Neurological Disorders

Volumn 1, Issue 2, 2008, Pages 99-114

  Gold, Ralf ^a   Hohlfeld, Reinhard ^b   Toyka, Klaus V ^c  

^a ST JOSEF HOSPITAL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Acetylcholine receptor; Immuno adsorption; Immunoglobulins; Immunosuppression; Muscle specific kinase; Plasmapheresis; Thymoma

Indexed keywords

EID: 84993776000     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285608093888     Document Type: Review

References (40)

1. Arsura, E., Brunner, N.G., Namba, T. and Grob, D. (1985) High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 42: 1149-1153.
2. Besinger, U.A., Toyka, K.V., Homberg, M., Heininger, K., Hohlfeld, R. and Fateh-Moghadam, A. (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33: 1316-1321.
3. Buchwald, B., Dudel, J. and Toyka, K.V. (1998) Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome. Ann NY Acad Sci 841: 659-669.
4. Bufler, J., Kahlert, S., Tzartos, S., Toyka, K.V., Maelicke, A. and Franke, C. (1996) Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J Physiol (Lond) 492(Pt 1): 107-114.
5. Drachman, D.B. (1987) Present and future treatment of myasthenia gravis. N Engl J Med 316: 743-745.
6. Drachman, D.B. (1994) Myasthenia gravis. N Engl J Med 330: 1797-1810.
7. Drachman, D.B., Jones, R.J. and Brodsky, R.A. (2003) Treatment of refractory myasthenia: “Rebooting” with high-dose cyclophosphamide. Ann Neurol 53: 29-34.
8. Dudel, J., Birnberger, K.L., Toyka, K.V., Schlegel, C. and Besinger, U. (1979) Effects of myasthenic immunoglobulins and of prednisolone on spontaneous miniature end-plate potentials in mouse diaphragms. Exp Neurol 66: 365-380.
9. Farrugia, M.E., Robson, M.D., Clover, L., Anslow, P., Newsom-Davis, J., Kennett, R. et al. (2006) MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129: 1481-1492.
10. Flachenecker, P., Taleghani, B.M., Gold, R., Grossmann, R., Wiebecke, D. and Toyka, K.V. (1998) Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. Transfus Sci 19(Suppl): 43-46.
11. Gajdos, P., Chevret, S., Clair, B., Tranchant, C. and Chastang, C. (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann of Neurol 41: 789-796.
12. Gajdos, P., Chevret, S. and Toyka, K. (2008) Intravenous immunoglobulin for myasthenia gravis - art. no. CD002277. Cochrane Database of Systematic Reviews 2277.
13. Gajdos, P., Tranchant, C., Clair, B., Bolgert, F., Eymard, B., Stojkovic, T. et al. (2005) Treatment of Myasthenia Gravis exacerbation with intravenous immunoglobulin - A randomized double-blind clinical trial. Arch Neurol 62: 1689-1693.
14. Gold, R., Dalakas, M.C. and Toyka, K.V. (2003) Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2: 22-32.
15. Graeber, G.M. and Tamim, W. (2000) Current status of the diagnosis and treatment of thymoma. Semin Thorac Cardiovasc Surg 12: 268-277.
16. Gronseth, G.S. and Barohn, R.J. (2000) Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55: 7-15.
17. Heininger, K., Hartung, H.-P., Toyka, K.V., Gaczkowski, A. and Borberg, H. (1987) Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels. Ann N Y Acad Sci 505: 898-900.
18. Heininger, K., Toyka, K.V., Gaczkowski, A., Borberg, H., Hartung, H.P. and Grabensee, B. (1986) Semi-selective removal of pathogenic factors in neurologic disease. Plasma therapy 7: 351-357.
19. Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A. and Vincent, A. (2001) Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368.
20. Hohlfeld, R., Melms, A., Schneider, C., Toyka, K.V. and Drachman, D.B. (2003) Therapy of myasthenia gravis and myasthenic syndromes. In Brandt, T., Caplan, L.R., Dichgans, J., Diener, H.C. and Kennard, C. (eds) Neurological disorders: course and treatment. Elsevier Stuttgart, 1341-62.
21. Hohlfeld, R., Michels, M., Heininger, K., Besinger, U. and Toyka, K.V. (1988) Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 38: 258-261.
22. Hohlfeld, R., Toyka, K.V., Besinger, U.A., Gerhold, B. and Heininger, K. (1985) Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 17: 238-242.
23. Hohlfeld, R. and Wekerle, H. (1999) The immuno-pathogenesis of myasthenia gravis. In Engel, A.G. (ed.) Myasthenia gravis and myasthenic syndromes. OxfordOxford University Press, 87-110.
24. Kirchner, T., Schalke, B., Melms, A., von Kugelgen, T. and Muller-Hermelink, H.K. (1986) Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 52: 237-257.
25. Leite, M.I., Strobel, P., Jones, M., Micklem, K., Moritz, R., Gold, R. et al. (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative, MG. Ann of Neurol 57: 444-448.
26. Mertens, H.G., Hertel, G., Reuther, P. and Ricker, K. (1981) Effect of immunosuppressive drugs (azathioprine). Ann NY Acad Sci 377: 691-699.
27. Muller-Hermelink, H.K. and Marx, A. (2000) Thymoma. Curr Opin Oncol 12: 426-433.
28. Muscle Study Group. (2008) A trial of mycophenolate mofetil with prednisolone as initial immunotherapy in myasthenia gravis. Neurology 71: 394-399.
29. Palace, J., Newsom-Davis, J., Lecky, B. and Myasthenia Gravis Study Grp. ( 1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50: 1778-1783.
30. Schneider-Gold, C., Gajdos, P., Toyka, K.V., Hohlfeld, R.R. (2005) Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev CD002828.
31. Schneider, C., Gold, R., Reiners, K. and Toyka, K.V. (2001) Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 46: 79-82.
32. Schneider-Gold, C., Hartung, H.P. and Gold, R. (2006) Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases. Muscle & Nerve 34: 284-291.
33. Schneider-Gold, C. and Toyka, K.V. (2007) Myasthenia gravis: Pathogenesis and immunotherapy (English version). Dtsch Ärzteblatt 104: A420-A426.
34. Strobel, P., Bauer, A., Puppe, B., Kraushaar, T., Krein, A., Toyka, K. et al. (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22: 1501-1509.
35. Tindall, R.S., Rollins, J.A., Phillips, J.T., e Greenlee, R.G., Wells, L. and Belendiuk, G. (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316: 719-724.
36. Toyka, K.V. and Gold, R. (2007) Treatment of myasthenia gravis. Schweiz Arch Neurol Psychiatr 158: 309-321.
37. Vincent, A., Bowen, J., Newsom-Davis, J. and McConville, J. (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets. Lancet Neurol 2: 99-106.
38. Wekerle, H. and Ketelsen, U.P. (1977) Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1: 678-680.
39. Witte, A.S., Cornblath, D.R., Parry, G.J., Lisak, R.P. and Schatz, N.J. (1984) Azathioprine in the treatment of myasthenia gravis. Ann Neurol 15: 602-605.
40. Zinman, L., Ng, E. and Bril, V. (2007) IV immunoglobulin in patients with myasthenia gravis - A randomized controlled trial. Neurology 68: 837-841.